Adult ADHD: DSM-5-TR Diagnostic Criteria, Executive Dysfunction, and Pharmacotherapy Algorithms

The Neurobiology of Adult Executive Dysfunction

Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly heritable neurodevelopmental condition characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with social, academic, and occupational functioning. Historically mischaracterized as an exclusively pediatric behavioral condition outgrown in adolescence, longitudinal cohort studies confirm that 50% to 65% of individuals diagnosed in childhood continue to experience clinically significant symptoms into adulthood.

Neurobiologically, ADHD is grounded in structural and functional connectivity deficits within the fronto-striatal, fronto-parietal, and default mode networks of the brain. The core pathophysiology centers on catecholaminergic transmission: hypofunction of Dopamine (DA) and Norepinephrine (NE) neurotransmission within the prefrontal cortex (PFC) impairs signal-to-noise processing. D1 dopamine receptor signaling is essential for suppressing background environmental distractors, while alpha-2A adrenergic receptor stimulation enhances target neuronal signals. Deficiencies in these pathways manifest clinically as profound executive dysfunction—deficits in working memory, task initiation, sustained focus, cognitive flexibility, and time perception ('time blindness').

DSM-5-TR Diagnostic Criteria and Clinical Assessment

Diagnosing ADHD in adults presents significant clinical complexity because overt physical hyperactivity (such as running or climbing) frequently transmutes in adulthood into subjective internal restlessness, racing thoughts, chronic fidgeting, or verbal impulsivity. Under the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), adult diagnosis requires:

- At least 5 symptoms from either the Inattention cluster or the Hyperactivity/Impulsivity cluster (in contrast to 6 required for children). - Inattention Symptoms: Frequent careless errors, difficulty sustaining focus in lengthy meetings, failure to follow through on multi-step instructions, chronic disorganization, avoidance of sustained mental effort, misplacing essential items, high distractibility by extraneous stimuli, and forgetfulness in daily routines. - Hyperactivity/Impulsivity Symptoms: Restlessness when seated, leaving seat inappropriately, feelings of being 'driven by a motor', excessive talking, interrupting conversations, and difficulty waiting turns. - Age-of-Onset Requirement: Several symptoms must have been present prior to age 12, documented through historical academic report cards or collateral family interviews. - Impairment Criterion: Clear evidence of functional impairment across two or more independent settings (e.g., occupational performance, home organization, interpersonal relationships).

Pharmacological Algorithms: Psychostimulants

Psychostimulants represent the most extensively studied and clinically effective class in neuropsychiatry, demonstrating robust effect sizes between 0.8 and 1.0. Stimulants fall into two primary chemical classes: 1. Methylphenidate Formulations (e.g., Ritalin, Concerta, Focalin [dexmethylphenidate]): Primarily act as selective inhibitors of the Dopamine Transporter (DAT) and Norepinephrine Transporter (NET), blocking reuptake and prolonging catecholamine presence within prefrontal synapses. 2. Amphetamine Formulations (e.g., Adderall [mixed amphetamine salts], Vyvanse [lisdexamfetamine]): Exhibit dual mechanisms: competitively inhibiting DAT and NET while reversing the vesicular monoamine transporter 2 (VMAT2), causing active efflux of dopamine from cytoplasmic storage vesicles into the synaptic cleft. Lisdexamfetamine is an inactive prodrug chemically bound to L-lysine, cleaved by red blood cell enzymes in the gastrointestinal tract, providing smooth 14-hour coverage with lower abuse potential.

Baseline cardiovascular evaluation—including resting blood pressure, heart rate, personal history of syncope, and familial history of sudden cardiac death—is mandatory prior to initiation.

Non-Stimulant Alternatives and Cognitive-Behavioral Therapy

For patients with contraindications to stimulants (active cardiovascular disease, uncontrolled severe hypertension, structural cardiac anomalies, active substance use disorder, or severe tics), non-stimulant pharmacotherapy is indicated: - Atomoxetine (Strattera): A selective norepinephrine reuptake inhibitor (NRI) lacking dopaminergic abuse liability. Requires 4 to 6 weeks of daily dosing to achieve steady-state therapeutic benefit. - Viloxazine Extended-Release (Qelbree): A multimodal serotonin-norepinephrine modulating agent approved for pediatric and adult ADHD. - Alpha-2 Adrenergic Agonists (Clonidine, Guanfacine Extended-Release): Directly stimulate post-synaptic alpha-2A receptors in the prefrontal cortex, strengthening synaptic connectivity; highly beneficial for emotional dysregulation and comorbid insomnia. - Cognitive-Behavioral Therapy (CBT): Pharmacotherapy is optimized when paired with adult ADHD-focused CBT, coaching in external compensatory systems (visual calendars, timers, structured task chunking), and environmental workplace modifications.